Lyell Immunopharma

$7.52 0.00% ($0.00)

Get ready to invest

About Lyell Immunopharma

Lyell Immunopharma, Inc is a T cell reprogramming company. The Company offers T cells to cure patients with solid tumors. Its technologies are designed to be applied in a target and agnostic manner to chimeric antigen receptor (CAR), tumor-infiltrating lymphocytes (TIL) and T cell receptor (TCR) therapies to improve the properties of T cells to eradicate solid tumors. It builds a multi-modality product pipeline across solid tumor indications with unmet needs and anticipate having investigational new drug application (IND). It offers Gen-R and Epi-R technology platforms. Its Gen-R is its ex vivo genetic reprogramming technology to overcome T cell exhaustion. Its Epi-R is an ex vivo epigenetic reprogramming technology to create a population of T cells with durable stemness. Epi-R is designed to generate populations of T cells which have this property of durable stemness. It utilizes its Gen-R and Epi-R technology platforms to develop a multi-modality product pipeline.

Popular Stocks	Price	Change
Bed Bath & Beyond BBBY	$19.47 21.69%	21.69%
AMTD International ADR AMTD	$2.8899 27.87%	27.87%
Nu Holdings NU	$5.615 19.98%	19.98%
AMC AMC	$24.5295 1.32%	1.32%
AMD AMD	$100.33 0.67%	0.67%
SoFi SOFI	$7.625 0.07%	0.07%
Ginkgo Bioworks Holdings DNA	$3.8 8.88%	8.88%
Snap SNAP	$12.59 2.86%	2.86%
Carnival CCL	$11.205 4.62%	4.62%
fuboTV FUBO	$6.405 46.23%	46.23%